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Summary. The administration of cyclosporin A (CyA) after
autologous haematopoietic stem cell transplantation (HSCT)
induces a systemic autoimmune syndrome mimicking graft-
vs.-host disease (GVHD). This syndrome, termed autologous
GVHD has notable anti-tumour activity in animal studies.
We intended to induce autologous GVHD with CyA in
patients undergoing an autologous HSCT. We prospectively
studied 118 patients with miscellaneous malignancies
undergoing an autologous HSCT with low-dose CyA to
characterize the clinical syndrome, its frequency and
clinical course, and to determine the factors affecting its
incidence. Patients received CyA from d 21 through to
d 28, first starting at 2 mg/kg intravenously and then orally
as soon as feasible. The dose was adjusted to achieve pre-
dose blood levels around 100 ng/ml. A skin biopsy was
performed when a skin rash was observed. Thirty-three
percent of the patients developed clinical GVHD: clinical
stage 1 in 21 patients, stage 2 in seven patients, and stage 3
in three patients. Although total body irradiation (TBI) or
high-dose cyclophosphamide were previously thought to be
needed, autologous GVHD occurred in five out of 12
patients (42%) after a preparative regimen with high-dose
melphalan alone. Autologous GVHD was significantly more
frequent in patients older than 33 years, in patients who
had received high doses of granulocyte-macrophage colony
forming units (CFU-GM) and in those with a diagnosis of
myeloid malignancy, compared with those with lymphoid
malignancies or solid tumours. A significant negative
association was also found with HLA-DR6. In lymphoma
patients, GVHD occurred more frequently in advanced
disease than in first or second complete remission (CR1±
2) patients. All other factors studied were not predictive for
GVHD. In conclusion, CyA-induced GVHD is reproducibly
and safely induced with doses of CyA adapted to achieve
blood levels around 100 ng/ml. In retrospective analysis,
there was no survival advantage for patients with GVHD.
Phase III trials with this approach are needed to evaluate its
anti-tumoral effect.
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Graft-vs.-host disease (GVHD) is a major cause of death
after allogeneic haematopoietic stem cell transplantation
(allo-HSCT). However, it is associated with substantial anti-
tumour activity (Weiden et al, 1979, 1981). This anti-
tumoral effect, termed graft-vs.-leukaemia effect (GVL), was
confirmed by a large retrospective study (Horowitz et al,
1990) showing a lower rate of relapse after allogeneic HSCT
in patients with clinical GVHD [particularly chronic GVHD
in acute myeloid leukaemia (AML) and chronic myeloid
leukaemia (CML) patients and acute GVHD in acute
lymphoblastic leukaemia (ALL) patients] and by the ability
of donor lymphocyte infusions (DLIs) to induce complete
remissions in patients relapsing after allo-HSCT (Baron &
Beguin, 2000). A graft-vs.-tumour effect has also been
evidenced in multiple myeloma (Verdonck et al, 1996; Bertz
et al, 1997) and breast cancer (Eibl et al, 1996). The
procedure-related toxicity and mortality are lower after
autologous haematopoietic stem cell transplantation (auto-
HSCT) than after allo-HSCT. However, auto-HSCT is
associated with a high relapse rate owing, at least in part,
to the absence of a graft-vs.-tumour effect associated with
GVHD (Gale & Champlin, 1984; Kersey et al, 1987).
Although histocompatibility differences are thought to
initiate the anti-host response of the graft, a syndrome with
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pathology identical to GVHD can occur after autologous
bone marrow transplantation (BMT) (Thien et al, 1981).
This syndrome, termed autologous or syngeneic GVHD,
occurs spontaneously in 5±10% of patients receiving an
autologous or syngeneic HSCT (Hood et al, 1987; Byrne et al,
1997) and may be induced by the administration of
cyclosporin A (CyA) after autologous HSCT in animals
(Glazier et al, 1983; Bryson et al, 1989) and humans (Jones
et al, 1989; Talbot et al, 1990; Carella et al, 1991; Kennedy
et al, 1993; Yeager et al, 1993; Pati et al, 1996; Giralt et al,
1997; Gruhn et al, 1998). This syndrome has notable anti-
tumour activity in animal studies (Geller et al, 1989; Charak
et al, 1992a; Bryson et al, 1999) and there is also some
indication of an anti-tumour effect in humans (Byrne et al,
1997). We prospectively studied 118 patients undergoing
an autologous HSCT with low-dose CyA to characterize the
clinical syndrome, its frequency and clinical course, as well
as to determine the factors affecting its incidence, including
HLA typing.
PATIENTS AND METHODS
Patients. One hundred and eighteen patients undergoing
an autologous HSCT between December 1993 and October
1997 received CyA in order to induce autologous GVHD. Of
these 118 patients, eight had an inadequate follow-up and
13 received CyA for less than 14 d (no drug prescription in
one patient, patient refusal in one and early regimen-related
or infectious complications in 11 patients). These complica-
tions were unrelated to CyA, but their resolution was
thought to be potentially delayed by CyA, which was thus
stopped. Thus, 97 patients, 38 men and 59 women, aged
47 ^ 14 years (range 3±66 years, including eight children)
were fully evaluable. Their diagnoses were multiple mye-
loma (n  18), non-Hodgkin's lymphoma (NHL; n  14),
Hodgkin's disease (n  8), AML (n  7), CML (n  4),
myelodysplastic syndrome (MDS; n  2), breast cancer
(n  35) or other solid tumours (n  9). The protocol was
approved by the Ethics Committee at the University of LieÁge
and patients gave consent to participate in the study.
Chemotherapy, transplant and supportive care. The con-
ditioning regimens were STAMP V (cyclophosphamide,
thiotepa, carboplatin) (Antman et al, 1992) in 35 patients,
BEAM [BCNU (carmustine), etoposide, cytarabine, melpha-
lan] in 14 patients, melphalan in 12 patients, total body
irradiation (TBI) and cyclophosphamide ^Ara-C in 15
patients, TBI and melphalan in four patients, busulphan
and cyclophosphamide or other drugs in seven patients, as
well as miscellaneous regimens including TBI (n  2),
cyclophosphamide (n  3) or melphalan (n  5). Patients
were grafted with peripheral blood stem cells and 88 of them
received granulocyte colony stimulating factor (G-CSF) to
accelerate neutrophil recovery.
Induction of autologous GVHD. Patients received CyA from
d 21 through to d 28, first as an intravenous (i.v.) 12-h
infusion starting at 2 mg/kg and then orally in one or two
doses as soon as feasible. CyA levels were measured by a
commercially available radioimmunoassay. CyA dose was
adjusted to maintain pre-dose whole blood levels around
100 ng/ml. CyA was stopped early in four patients on d 14,
d 18, d 24 and d 25 because of the development of grade 2
GVHD. Patients were examined daily during hospitalization
and twice weekly after discharge. To confirm the diagnosis
of GVHD, a punch biopsy was performed where a skin rash
was observed.
Histopathological examination. Specimens were fixed in
buffered formalin and embedded in paraffin. Six-micron
thick sections were stained using haematoxylin and eosin.
Histopathological grading of cutaneous GVHD was based
following Lerner's classification (Lerner et al, 1974).
Previous works have revealed that immunohistochemistry
may be valuable in increasing the sensitivity to detect early
changes of cutaneous GVHD (Pimpinelli et al, 1993; Pierard
et al, 1998a, 1998b; Hermans-Le et al, 1999). In particular,
keratinocytes overexpress the L1 protein and dermal
dendrocytes are increased in size and number. Hence, the
three-step avidin±biotin method was applied using the Mac
387 (1:100, Dakopatts, Copenhagen, Denmark), UCLH-1
(1:100, Dakopatts) and anti-factor XIIIa (1:300, Behring,
Marburg, Germany) antibodies aiming at detecting intra-
cellular L1 protein (monocytes-macrophages and altered
keratinocytes), CD45R0 (T lymphocytes) and factor XIIIa
(dendrocytes) respectively. After rinsing in Tris-buffered
saline, sections were covered with alkaline phosphatase-
conjugated streptavidin (LSAB1 kit prediluted, Dakopatts).
New Fuschin (Dakopatts) was used as a chromogen for
5 min. Sections were counterstained with haematoxylin
and mounted in glycergel (Dakopatts). The slides were
reviewed by two experienced dermatopathologists.
Statistical analysis. Potential predictive factors for auto-
logous GVHD analysed included daily or total dose and
duration of i.v. or oral CyA, CyA blood levels, age, sex,
diagnosis, disease status at transplant, conditioning regi-
men, first or second transplant, CD34 selection, cell dose
[nucleated cells (NC), granulocyte-macrophage colony
forming units (CFU-GM), erythroid burst-forming units
(BFU-E), mixed lineage CFU (CFU-Mix), CD341 cells], use
of G-CSF, speed of neutrophil, platelet and erythroid
engraftment, and HLA A, B and DR typing.
Univariate comparison of the rate of autologous GVHD in
different groups was performed by the Chi square test or
Fisher's exact test, where appropriate, using Graphpad
Prism (Graphpad software, San Diego, CA, USA). Multi-
variate analysis by stepwise logistic regression was per-
formed with SAS (SAS Institute, Cary, NC, USA). Actuarial
survival analyses were performed in Prism using the
Kaplan±Meier product-limit method. Comparisons between
survival curves were performed using the log-rank test.
RESULTS
Overall results
Thirty-two patients (33%) developed clinical GVHD (Tables I
and II). This syndrome occurred 4±33 d (median 19 d)
following HSCT and persisted for 2±27 d (median 8 d).
Mean doses of i.v. and oral CyA administered were 2´11 ^
0´78 mg/kg/d (range 0´76±5´95) and 2´15 ^ 1´29 mg/
kg/d (range 0´65±9´38) respectively. Thirty-seven patients
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developed a skin rash and the skin biopsy confirmed
cutaneous GVHD in 31 of them. According to Glucksberg
criteria (Thomas et al, 1975), the clinical stage was 1 in 21
patients, 2 in seven patients and 3 in three patients. The
rash did not involve any particular part of the body. Four
patients developed clinical stage 1 gastrointestinal GVHD.
This gastrointestinal GVHD was isolated in one patient, but
was associated with cutaneous GVHD in the other three
patients. This was confirmed by biopsies in two patients. No
patient developed liver GVHD. GVHD was spontaneously
reversible in 28 patients and resolved after premature
withdrawal of CyA in three patients and with a short course
of corticosteroids in addition to withdrawal of CyA in one
patient. Alternatively, among the 11 patients receiving CyA
for less than 14 d because of early complications and thus
not fully evaluable, four additional patients developed a skin
rash, which corresponded to GVHD in two of them.
Predictive factors
Univariate analysis of potential predictive factors showed
that autologous GVHD was significantly more frequent in
patients older than 33 years (38% vs. 13% in younger
patients, P  0´043) and in patients with a diagnosis of
myeloid malignancy (62%) compared with those with
lymphoid malignancies (32%) or solid tumours (25%)
(P  0´048). A significant negative association was also
found with HLA-A10 (12% vs. 38% of patients without
HLA-A10, P  0´049) and HLA-B16 (0% vs. 37% in
patients without HLA-B16) (P  0´047). The presence of
B16 and A10 were strongly associated in our patients
(P  0´0001). All other factors studied were not predictive
of GVHD in univariate analysis (Table III). Subgroup
analysis showed that, in lymphoma patients, the rate of
GVHD was lower in first or second complete remission
(CR1±2) (one out of 11 or 9%) than in more advanced
Table I. Clinical autologous GVHD according to the underlying disease.
Underlying disease Number of patients with GVHD
/total number of patients
Number of patients with
cutaneous GVHD




(%) Stage 1 Stage 2 Stage 3 Stage 1 Stage 1 Stage 2 Stage 3
Multiple myeloma 6/18 (33%) 4 2 0 1 5 1 0
NHL 3/14 (21%) 2 0 1 1 2 1 0
Hodgkin's disease 4/8 (50%) 3 1 0 0 4 0 0
AML 4/7 (57%) 3 1 0 0 4 0 0
CML 2/4 (50%) 1 0 1 1 0 2 0
MDS 2/2 (100%) 1 1 0 0 2 0 0
Breast cancer 11/35 (31%) 7 2 1 1 9 2 0
Soft tissue sarcoma 0/4 (0%) 0 0 0 0 0 0 0
Neuroblastoma 0/2 (0%) 0 0 0 0 0 0 0
Ovarian cancer 0/1 (0%) 0 0 0 0 0 0 0
Testicular cancer 0/2 (0%) 0 0 0 0 0 0 0
Total 32/97 (33%) 21 7 3 4 26 6 0
Table II. Clinical autologous GVHD according to the conditioning regimen.
Conditioning regimen Number of patients Number (%) of patients with GVHD
STAMP V 5 11 (31%)
BEAM 14 4 (29%)
Mel 12 5 (42%)
Cy 1 Ara-C 1 TBI 8 5 (63%)
Cy 1 TBI 7 2 (29%)
Mel 1 TBI 4 1 (25%)
Bu 1 Cy 4 2 (50%)
Bu 1 others 3 0 (0%)
TBI 1 others 2 1 (50%)
Cy 1 others 3 1 (33%)
Mel 1 others 5 0 (0%)
STAMP V, cyclophosphamide, thiotepa and carboplatin; BEAM, BCNU, etoposide, cytarabine and
melphalan; Mel, melphalan; Cy, cyclophosphamide; Ara-C, cytarabine; TBI, total body irradiation;
Bu, busulphan.
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Table III. Predictive factors of CyA-induced autologous GVHD.
Predictive factor Number of patients % with GVHD P-value
Sex: Male 38 37 NS
Female 59 31
Age: , 33 years 19 11 0´0430
$ 33 years 78 38
Route of CyA administration: orally 14 36 NS
i.v. 8 50
orally 1 i.v. 75 31
Average total dose of CyA: , 45 mg/kg 30 42 NS
45±65 mg/kg 42 21
. 65 mg/kg 25 36
Average daily dose of CyA: , 1´5 mg/kg 30 33 NS
1´6±2´0 mg/kg 31 32
. 2´0 mg/kg 36 33
Average pre-dose CyA blood levels: , 100 ng/ml 39 28 NS
100±120 ng/ml 28 39
. 120 ng/ml 30 33
Disease: Myeloid malignancies 13 62 0´0481
Lymphoid malignancies 40 32
Solid tumours 44 25
Conditioning regimen: TBI 21 43 NS
No TBI 76 30
Consecutive number of transplant: First 91 34 NS
Second 6 17
CD34 selection: Yes 15 20 NS
No 82 35
Cell dose
NC: , 0´5 108/kg 15 20 NS
0´5±3 108/kg 23 48
3±5 108/kg 31 35
. 5 108/kg 28 25
CFU-GM: , 100 104/kg 58 29 NS
. 100 104/kg 39 38
BFU-E: , 40 104/kg 33 27 NS
40±150 104/kg 28 39
. 150 104/kg 36 34
CFU-mix: , 4 104/kg 32 44 NS
4±25 104/kg 33 21
. 25 104/kg 32 37
CD341 cells: , 3 106/kg 15 33 NS
3±5 106/kg 28 32
5±10 106/kg 27 33
. 10 106/kg 27 36
G-CSF use: Yes 88 31 NS
No 9 56
Number of days to 500 neutrophils: , 15 85 29 0´057 (NS)
. 15 12 58
Number of days to 1% reticulocytes: , 11 32 38 NS
12±15 38 26
. 15 27 37
Number of days to 20 000 platelets: , 10 38 34 NS
11±15 31 29
16±30 16 38
. 30 12 33
HLA A10*: Yes 17 12 0´0485
No 80 38
B16: Yes 10 0 0´0468
No 87 37
DR6: Yes 22 18 NS
No 75 37
*Other HLA subgroups were tested and found not significantly associated with autologous GVHD, including A 1, 2, 3, 9 and 19, B 5, 7, 8, 12,
15, 17, 27 and 35, and DR 1, 2, 3, 4, 5 and 7.
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patients (six out of 11 or 55%) (P  0´022). Among breast
cancer patients, GVHD was as frequent in the metastatic (six
out of 19) as in the adjuvant (five out of 16) setting.
Multivariate analysis by stepwise logistic regression was
performed with all variables except B16 (because there were
no cases of GVHD in patients with HLA-B16). Factors
significantly associated with autologous GVHD were a
diagnosis of myeloid malignancy compared with lymphoid
malignancies or solid tumours (P  0´012), a high dose of
CFU-GM infused (P  0´041) and absence of HLA-DR6
(P  0´041). Age was not found to be a significant predictor
because there was some statistical interaction between age
and presence of DR6 (more frequent in a young age,
P  0´046).
Toxicity associated with autologous GVHD
Patients were prospectively monitored for haematopoietic
recovery, regimen-related toxicities, infections and other
complications, as well as for bilirubin and creatinine levels.
Trilineage haematopoietic recovery and platelet or red blood
cell (RBC) transfusion rates were similar in patients with or
without autologous GVHD. There was no significant
increase in any toxicity parameter associated with the
development of autologous GVHD: grade 1 or 2 liver toxicity
occurred in 24 out of 65 (37%) patients without GVHD vs.
eight out of 32 (25%) patients with autologous GVHD;
grade 1 or 2 mucositis occurred in 26 out of 65 (40%)
patients without GVHD vs. 14 out of 32 (44%) patients with
autologous GVHD; and grade 1 or 2 gastrointestinal toxicity
occurred in 21 out of 65 (32%) patients and eight out of 32
(25%) patients respectively. Peak bilirubin or creatinine
values were comparable in the two groups. There was no
case of thrombotic thrombocytopenic purpura or any death
within 50 d of transplant in the 97 patients studied. Fever
occurred in 16 of the 32 patients (50%) with GVHD and in
39 of the 65 patients (60%) without GVHD (not significant;
NS). The number of days with fever or with i.v. antibiotics
did not differ. Finally, the occurrence of autologous GVHD
did not affect neutrophil or lymphocyte counts, or serum
creatinine, but elevated serum bilirubin levels occurred
more frequently in patients with stage 2 GVHD (three out of
six) than in those with stage 1 GVHD (nine out of 26) or no
GVHD (21 out of 65) (NS).
Long-term outcome
Overall survival of patients with GVHD (57% at 5 years) or
without GVHD (65% at 5 years) was not significantly
different (Fig 1). However, this analysis involved patients
with a variety of diagnoses and disease status at transplant.
Separate analyses of patients with lymphoma, multiple
myeloma or leukaemia did not show significant differences
in survival according to occurrence of autologous GVHD.
However, these subgroups were heterogeneous and the
balance between good-risk and high-risk patients with or
without GVHD was not achieved. This was only obtained
among patients with breast cancer: progression-free survi-
val at 4 years was 64% in patients with GVHD and 40% in
those without GVHD (NS).
DISCUSSION
Animal studies have shown that CyA treatment induced a
failure of T-cell differentiation, as well as autologous or
syngeneic GVHD associated with the development of
autoreactive CD81 cytotoxic T cells (Hess et al, 1985,
1994; Hess & Thoburn, 1997). In vitro lysis of a myeloma
cell line by CD81 splenic T cells from Lou M rats that
developed syngeneic GVHD has been demonstrated (Geller
et al, 1989). In vivo, a significant anti-tumour effect of
syngeneic GVHD was evidenced and enhanced by interferon
(IFN)-g (Noga et al, 1992). Another study in mice
demonstrated synergy between CyA and interleukin (IL)-2
in causing regression of lung metastases and improving
survival of animals with either melanoma or AML (Charak
et al, 1992b).
A few clinical studies have been performed in patients
with lymphoma (Jones et al, 1989; Vogelsang et al, 1989;
Carella et al, 1991; Pati et al, 1996; Gryn et al, 1997), AML
(Talbot et al, 1990; Yeager et al, 1992, 1993; Gruhn et al,
1998), myeloma (Giralt et al, 1997), breast cancer
Fig 1. A. Overall survival in patients with or without autologous
GVHD (NS). B. Progression-free survival in breast cancer patients
with or without autologous GVHD (NS).
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(Kennedy et al, 1993, 1994), ALL (Carella et al, 1991;
Gruhn et al, 1998) and CML (Carella et al, 1991). The
frequency of pathological and clinical autologous GVHD in
the five major studies is showed in Table IV. The number of
patients with myeloma and breast cancer in our study was
comparable to that of previous studies reporting trials in a
single disease (Kennedy et al, 1993; Giralt et al, 1997).
Among studies there were important discrepancies between
rates of clinical and pathological GVHD, some showing
similar rates and some a much lower incidence of clinical vs.
pathological GVHD. The distinction between clinical and
only pathological autologous GVHD may be of importance
because, in allogeneic HSCT, only clinical GVHD has been
shown to be associated with an anti-tumour effect. Therefore,
we focused on clinical GVHD and elected not to perform
systematic skin biopsies in the absence of any skin rash.
The diagnosis of skin eruptions developing after HSCT
requires close clinicopathological correlation because other
skin rashes histologically resemble GVHD (Johnson &
Farmer, 1998). The positive Lerner's criteria for GVHD
(Lerner et al, 1974) are used in our practice in combination
with exclusion criteria and immunohistochemical assess-
ment to refine the diagnosis. Positive immunohistochemical
criteria for GVHD include the overexpression of the L1
protein in keratinocytes and hyperplasia of the dendrocyte
population (Pierard et al, 1998a, 1998b; Hermans-Le et al,
1999). In contrast, disordered epidermal maturation, super-
ficial dyskeratotic keratinocytes and normal dendrocytes
suggest a cytotoxic effect of chemotherapy. Vasculitis,
eosinophils, dendrocytoclasia and variable L1-protein load
in keratinocytes favour a drug reaction. Viral exanthemas
only marginally affect the dendrocyte population and the
pattern of L1-protein labelling. Finally, the eruption of
lymphocyte recovery is almost indistinguishable from low-
grade allogeneic reactions although the L1-protein expression
in the epidermis does not appear to be boosted at the same
level.
As in previous studies, clinical autologous GVHD in our
study was generally self-limited and mostly confined to the
skin. However, clinical gastrointestinal GVHD may have
occurred in very few patients and serum bilirubin levels
tended to be more frequently elevated (although not
reaching levels characteristic of stage 1 liver GVHD) in
patients with stage 2 GVHD (three out of six) compared with
those with stage 1 GVHD (nine out of 26) or no GVHD (21
out of 65), suggesting that mild liver GVHD may also be a
feature of autologous GVHD.
The global occurrence of clinical autologous GVHD in
our study was 33% (57% in AML patients). This is in
concordance with Yeager et al (1992) (53% in AML
patients) and Kennedy et al (1993) (Table IV). As yet, the
only known predictive factor of autologous GVHD occur-
rence in humans has been the dose of CyA in patients with
breast cancer (Kennedy et al, 1993), although this finding
was not confirmed in this or two other studies (Yeager et al,
1992; Giralt et al, 1997). As a fixed dose of CyA may be
associated with high CyA blood levels in some patients, we
chose to adapt the dose to obtain pre-dose blood levels
around 100 ng/ml and the dose necessary to achieve this
varied considerably. However, the rate of autologous GVHD
was not influenced by the dose given or by CyA blood levels.
The strongest predictive factor in multivariate analysis
was a diagnosis of myeloid malignancy vs. a diagnosis of
lymphoid malignancy or solid tumour. This confirmed what
could be suspected from previous studies (Table IV) and
could relate to differences in preparative regimens used in
these three groups of diseases, as well as alterations of
thymic function and/or of T cells in the graft owing to
the underlying disease and previous chemotherapy. For
instance, the incidence of GVHD was lower in lymphoma
patients in CR1±2 than in more advanced patients. In
patients with multiple myeloma, the rate of clinical
autologous GVHD was 33% (higher than the 7% observed
in another study (Giralt et al, 1997)), thus denying a role for





regimen Dose of CyA
% of patients with
pathological GVHD
% of patients with
clinical GVHD
Yeager et al (1992) 19 AML Bu 1 Cy 1 mg/kg i.v. (n  7)
2´5 mg/kg i.v. (n  8)
3´75 mg/kg i.v. (n  4)
79 53
Giralt et al (1997) 14 Multiple
myeloma
Bu 1 Cy 1
Thiot
i.v. CyA with blood levels:
50±150 ng/ml (n  7)





Kennedy et al (1993) 51 Breast cancer Cy 1 Thio 1 mg/kg i.v. (n  7)
2´5 mg/kg i.v. (n  31)







Gruhn et al (1998) 20 AML, ALL, NHL Miscellaneous 1´5 mg/kg i.v. 50 25
Baron & Beguin (2000) 97 Miscellaneous Miscellaneous i.v. or oral CyA with blood
levels around 100 ng/ml
± 33
AML, acute myeloid leukaemia; ALL, acute lymphoid leukaemia; NHL, non-Hodgkin's lymphoma; Bu, busulphan; Cy, cyclophosphamide;
Thiot, thiothepa; CyA, cyclosporin A.
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T-cell dysfunction in the low incidence of clinical autologous
GVHD previously reported.
Induction of autologous GVHD in man was thought to
require either TBI or Cy in the preparative regimen (Jones
et al, 1989; Hess & Thoburn, 1997). We report here for the
first time that CyA can also induce autologous GVHD after a
preparative regimen with high-dose melphalan alone in
42% of patients with multiple myeloma. This finding may
permit the development of new strategies of post-transplant
immunotherapy, for example combining CyA with inter-
feron, in this still incurable disease. Indeed, interferon
gamma has been shown to augment the probability of CyA-
induced autologous GVHD in animal (Charak et al, 1992a;
Noga et al, 1992), as well as human (Kennedy et al, 1994;
Gryn et al, 1997), studies, but there is little experience with
interferon alpha to date.
Another predictive factor evidenced in our study was
the age of the patients: the incidence of autologous GVHD
was lower in children than in adults, as is the case after
allogeneic GVHD (Ramsay et al, 1982). Age was not
retained as a predictive factor in multivariate analysis
because of statistical interaction between age and HLA-DR6
(HLA-DR6 more frequent in young patients), the latter
being entered first in the model.
The dose of CFU-GM infused had a significant impact
upon the rate of autologous GVHD, although the dose of
nucleated cells or mononucleated cells did not. This may
signify that lymphocytes or monocytes in the graft are not
primarily responsible for the syndrome that is caused by
cells newly produced from transplanted haematopoietic
stem cells.
We also found a significant association between some
HLA subgroups and occurrence of autologous GVHD:
autologous GVHD was significantly more frequent in
patients without HLA-DR6 (or without B16). CD81 T cells
responsible for autologous GVHD recognize MHC class II
antigens in combination with a peptide from the invariant
chain (Hess & Thoburn, 1997). Further studies are needed
to determine whether some HLA class II antigens are more
or less susceptible to recognition by such CD81 T cells.
However, this association may also just be a chance finding
when examining a large set of HLA subgroups, as no
particular HLA class I or II antigen has been shown to be
more prone to cause either acute or chronic GVHD in the
allogeneic setting (Martin et al, 1998).
The aim of this trial was to characterize the clinical GVHD
syndrome and determine factors affecting its incidence.
Therefore, patients with a variety of ages, diseases and
conditioning regimens were included. However, the final
purpose of administering CyA is not to induce autologous
GVHD, but to improve disease-free survival. A retrospective
analysis of our patients did not show a survival advantage
for those patients presenting with autologous GVHD.
However, our group of patients was heterogeneous as far
as the primary diagnoses and disease status were concerned,
therefore precluding any final conclusion on the clinical
impact of autologous GVHD on tumour control. The largest
group of patients with breast cancer was the only one clearly
well-balanced between high (metastatic) and standard
(adjuvant) risks. There was a trend towards a better
progression-free survival (PFS) beyond 2 years in patients
with GVHD, but this was not statistically significant. Longer
follow-up is needed to clarify this critical issue. It is now
necessary to carry out prospective randomised studies of
autologous GVHD induction by cyclosporin in well-defined
groups of subjects, particularly in high-risk breast cancer
patients. These studies will need to be multicentric and a
common approach to the diagnosis of autologous GVHD will
be critical.
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